The effect of melatonin on breast cancer treatment

Year 2025, Volume: 3 Issue: 3, 139 - 146, 29.10.2025

Derya Şimşekli

https://doi.org/10.61845/agrimedical.1688576

Abstract

This review is designed as a traditional review to determine the effects of melatonin on breast cancer. Breast cancer occurs as a result of abnormal and uncontrolled cell proliferation. It is one of the most common cancers among women in Turkey and globally. When diagnosed early, breast cancer offers a high chance of cure. Treatment options include chemotherapy, surgery, radiotherapy, and hormonotherapy. Melatonin, used in addition to these treatments, has been reported to have positive effects on the disease process and treatment-related complications. Melatonin, with its antioxidant, anti-inflammatory, antiproliferative, antiestrogenic, antiangiogenic, and immunomodulatory effects, can inhibit cell growth in breast cancer treatment. Furthermore, when used in addition to chemotherapy and radiotherapy, it has been found that it can enhance the body's sensitivity to these treatments, enhance the effectiveness of the treatment, improve patients' quality of life, and reduce fatigue. Further high-quality randomized controlled trials are recommended for the use of melatonin during chemotherapy and radiotherapy in patients with breast cancer.

Keywords

Chemotherapy , Breast cancer , Melatonin , Radiotherapy

Ethical Statement

Derleme olduğundan etik kurul iznine gerek yoktur.

Project Number

-

Meme kanseri tedavisinde melatoninin etkisi

Abstract

Bu derleme meme kanseri sürecinde melatoninin etkilerini belirlemek amacıyla geleneksel derleme olarak tasarlanmıştır. Meme kanseri, memedeki hücrelerin anormal ve kontrolsüz şekilde çoğalması sonucunda meydana gelmektedir. Türkiye ve dünyada görülme oranları bakımından kadınlar arasında ön sırada olan kanser türlerinden biridir. Meme kanseri, erken teşhis edildiğinde tedavi şansı yüksek olan bir kanser türüdür. Meme kanseri tedavisinde kemoterapi, cerrahi tedavi, radyoterapi ve hormonoterapi yer almaktadır. Bu tedavilere ek olarak kullanılan melatoninin, hastalık sürecinde ve tedaviye bağlı gelişen sorunlar üzerindeki olumlu etkileri bildirilmiştir. Melatonin, antioksidan, antiinflamatuar, antiproliferatif, antiöstrojenik, antianjiyojenik ve immünmodülatör etkileriyle meme kanseri tedavisinde hücre büyümesini engelleyebilir. Ayrıca kemoterapi ve radyoterapi sürecine ek olarak kullanıldığında bu tedavilere vücudun duyarlılığını arttırarak tedavinin etkisini arttırabileceği, hastaların yaşam kalitesinde artma meydana getirerek yorgunluğu azaltabileceği tespit edilmiştir. Melatoninin, meme kanseri olan hastaların kemoterapi ve radyoterapi sürecinde kullanılarak kanıt değeri yüksek daha fazla randomize kontrollü çalışma yapılması önerilmektedir.

Keywords

Kemoterapi , Meme kanseri , Melatonin , Radyoterapi

Ethical Statement

Derleme olduğundan etik kurul iznine gerek yoktur.

Supporting Institution

-

Project Number

-

Thanks

-

References

• Harbeck N, Penault-Llorca F, Cortes J, et al. Breast cancer. Nat Rev Dis Prim. 2019; 5(1):66.
• Subramani R, Lakshmanaswamy R. Complementary and alternative medicine and breast cancer. Prog Mol Biol Transl Sci. 2017; 151:231–74.
• Sanchez-Barcelo EJ, Mediavilla M, Alonso-Gonzalez C, Rueda N. Breast cancer therapy based on melatonin. Recent Pat Endocr Metab Immune Drug Discov. 2012; 6(2):108–16.
• Kubatka P, Zubor P, Busselberg D, et al. Melatonin and breast cancer: Evidences from preclinical and human studies. Crit Rev Oncol Hematol. 2018; 122:133–43.
• World Health Organization. Breast cancer. Accessed Jan 28, 2025. https://www.who.int/news-room/fact-sheets/detail/breast-cancer#:~:text=Overview,producing lobules of the breast
• World Cancer Research Fund. Breast cancer statistics. Accessed Jan 28, 2025. https://www.wcrf.org/preventing-cancer/cancer-statistics/breast-cancer-statistics
• International Agency for Research on Cancer. Cancer Over Time. Accessed Jan 28, 2025. https://gco.iarc.fr/overtime/en/dataviz/bars?sexes=1_2&mode=cancer&populations=792&years=2017&key=cum_risk&types=0_1
• T.C. Sağlık Bakanlığı. 2018 yılı verileri. Türkiye Kanser İstatistikleri. Accessed Jan 28, 2025. https://hsgm.saglik.gov.tr/depo/birimler/kanser-db/Dokumanlar/Istatistikler/Kanser_Rapor_2018.pdf
• Xu H, Xu B. Breast cancer: Epidemiology, risk factors and screening. Chinese J Cancer Res. 2023; 35(6):565–83.
• Park S, Lee DH, Jeon JY, et al. Serum 25-hydroxyvitamin D deficiency and increased risk of breast cancer among Korean women: a case–control study. Breast Cancer Res Treat. 2015; 152(1):147–54.
• Reeves R, Kaufman T. Mammography. In: StatPearls. StatPearls Publishing, Treasure Island (FL); Accessed Sep 28, 2025. https://www.ncbi.nlm.nih.gov/books/NBK559310/
• T.C. Sağlık Bakanlığı Sağlık Hizmetleri Genel Müdürlüğü. Meme kanseri korunma, tarama, tanı, tedavi ve izlem klinik rehberi. Accessed Jan 28, 2025. https://dosyamerkez.saglik.gov.tr/Eklenti/38131,memekanskr20200720pdf.pdf?0
• Wang L. Early diagnosis of breast cancer. Sensors (Switzerland). 2017; 17(7):1572.
• Viale G. The current state of breast cancer classification. Ann Oncol. 2012; 23:x207–10.
• Moodley J, Cairncross L, Naiker T, Constant D. From symptom discovery to treatment - women’s pathways to breast cancer care: A cross-sectional study. BMC Cancer. 2018; 18(1):312.
• National Center for Complementary and Integrative Health (NCCIH). Strategic Plan FY 2021-2025. Accessed Sep 28, 2025. https://www.nccih.nih.gov/about/nccih-strategic-plan-2021-2025
• Fathizadeh H, Mirzaei H, Asemi Z. Melatonin: An anti-tumor agent for osteosarcoma. Cancer Cell Int. 2019; 19(1):319.
• Fernández-Palanca P, Méndez-Blanco C, Fondevila F, Tuñón MJ, et al. Melatonin as an antitumor agent against liver cancer: An updated systematic review. Antioxidants. 2021; 10(1):103.
• Kim CH, Yoo YM. Melatonin induces apoptotic cell death via p53 in LNCaP cells. Korean J Physiol Pharmacol. 2010; 14(6):365–9.
• Sheibani M, Hosseinzadeh A, Fatemi I, Naeini AJ, Mehrzadi S. Practical application of melatonin for pancreas disorders: protective roles against inflammation, malignancy, and dysfunctions. Pharmacol Reports. 2025; 77(2):315–32.
• Innominato PF, Lim AS, Palesh O, et al. The effect of melatonin on sleep and quality of life in patients with advanced breast cancer. Support Care Cancer. 2016; 24(3):1097–1105.
• Yang WS, Deng Q, Fan WY, Wang WY, Wang X. Light exposure at night, sleep duration, melatonin, and breast cancer: A dose-response analysis of observational studies. Eur J Cancer Prev. 2014; 23(4):269–76.
• Pham TT, Lee ES, Kong SY, et al. Night-shift work, circadian and melatonin pathway related genes and their interaction on breast cancer risk: evidence from a case-control study in Korean women. Sci Rep. 2019; 9(1): 10982.
• Sedighi Pashaki A, Sheida F, Moaddab Shoar L, et al. A randomized, controlled, parallel-group, trial on the long-term effects of melatonin on fatigue associated with breast cancer and its adjuvant treatments. Integr Cancer Ther. 2023; 22: 15347354231168624.
• Pardi PC, Turri JAO, Bayer LHCM, et al. Biological action of melatonin on target receptors in breast cancer. Rev Assoc Med Bras. 2024; 70(3): e20231260.
• Nikolaev G, Robeva R, Konakchieva R. Membrane melatonin receptors activated cell signaling in physiology and disease. Int J Mol Sci. 2022; 23(1):471.
• Tse LH, Cheung ST, Lee S, Wong YH. Real-time determination of intracellular cAMP reveals functional coupling of gs protein to the melatonin MT1 receptor. Int J Mol Sci. 2024; 25(5):2919.
• Laborda-Illanes A, Sánchez-Alcoholado L, Boutriq S, et al. A new paradigm in the relationship between melatonin and breast cancer: Gut microbiota identified as a potential regulatory agent. Cancers (Basel). 2021; 13(13):3141.
• Andersen LPH, Werner MU, Rosenkilde MM, et al. Pharmacokinetics of oral and intravenous melatonin in healthy volunteers. BMC Pharmacol Toxicol. 2016; 17(1):8.
• Zetner D, Andersen LPH, Rosenberg J. Pharmacokinetics of alternative administration routes of melatonin: A systematic review. Drug Res (Stuttg). 2016; 66(04):169–73.
• Hardeland R. Melatonin metabolism in the central nervous system. Curr Neuropharmacol. 2010; 8(3):168–81.
• Harpsøe NG, Andersen LPH, Gögenur I, Rosenberg J. Clinical pharmacokinetics of melatonin: A systematic review. Eur J Clin Pharmacol. 2015; 71(8):901–9.
• Claustrat B, Leston J. Melatonin: Physiological effects in humans. Neurochirurgie. 2015; 61(2–3):77–84.
• Wang YM, Jin BZ, Ai F, et al. The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: A meta-analysis of randomized controlled trials. Cancer Chemother Pharmacol. 2012; 69(5):1213–20.
• Kubatka P, Bojková B, Mníchová-Chamilová M, Adámeková E, Ahlers I, Ahlersová E, et al. Effects of tamoxifen and melatonin on mammary gland cancer induced by N-methyl-N-nitrosourea and by 7, 12-dimethylbenz (a) anthracene, respectively, in female Sprague-Dawley rats. Folia Biol (Praha). 2001; 47(1):5–10.
• Yang A, Peng F, Zhu L, et al. Melatonin inhibits triple-negative breast cancer progression through the Lnc049808-FUNDC1 pathway. Cell Death Dis. 2021; 12(8):712.
• Junior RP, Chuffa LG de A, Simão VA, et al. Melatonin regulates the daily levels of plasma amino acids, acylcarnitines, biogenic amines, sphingomyelins, and hexoses in a xenograft model of triple negative breast cancer. Int J Mol Sci. 2022; 23(16):9105.
• Nimee F, Gioxari A, Papandreou P, et al. The effect of melatonin supplementation on cancer-related fatigue during chemotherapy treatment of breast cancer patients: A double-blind, randomized controlled study. Cancers (Basel). 2024; 16(4):802.
• Sedighi Pashaki A, Mohammadian K, Afshar S, et al. A randomized, controlled, parallel-group, trial on the effects of melatonin on fatigue associated with breast cancer and its adjuvant treatments. Integr Cancer Ther. 2021; 20: 1534735420988343.
• Mukhopadhyay ND, Khorasanchi A, Pandey S, et al. Melatonin supplementation for cancer-related fatigue in patients with early stage breast cancer receiving radiotherapy: A double-blind placebo-controlled trial. Oncologist. 2024; 29(2):e206–12.
• Seo K, Kim JH, Han D. Effects of Melatonin supplementation on sleep quality in breast cancer patients: a systematic review and meta-analysis. Healthc. 2023; 11(5):675.
• Palmer ACS, Zortea M, Souza A, et al. Clinical impact of melatonin on breast cancer patients undergoing chemotherapy; effects on cognition, sleep and depressive symptoms: A randomized, double-blind, placebo-controlled trial. PLoS One. 2020; 15(4):e0231379.
• Zetner D, Kamby C, Christophersen C, et al. Effect of melatonin cream on acute radiation dermatitis in patients with primary breast cancer: A double-blind, randomized, placebo-controlled trial. J Pineal Res. 2023; 75(1):e12873.
• Keshtpour Amlashi Z, Sheida F, Anbiaee R, et al. The effect of melatonin on increasing the health related quality of life in non-metastatic breast cancer patients: Three-year follow up a clinical trial. Integr Cancer Ther. 2024; 23: 15347354241237520.
• Ramos E, Egea J, López-Muñoz F, Gil-Martín E, Romero A. Therapeutic potential of melatonin counteracting chemotherapy-induced toxicity in breast cancer patients: A systematic review. Pharmaceutics. 2023; 15(6):1616.
• Pistiolis L, Khaki D, Kovács A, Olofsson Bagge R. The effect of melatonin intake on survival of patients with breast cancer—A population-based registry study. Cancers (Basel). 2022; 14(23):5884.
• Minella C, Coliat P, Amé S, et al. Protective role of melatonin in breast cancer: what we can learn from women with blindness. Cancer Causes Control. 2022; 33(1):1–13.
• Andersen LPH, Gögenur I, Rosenberg J, Reiter RJ. The safety of melatonin in humans. Clin Drug Investig. 2016; 36(3):169–75.
• Givler D, Givler A, Luther PM, et al. Chronic administration of melatonin: Physiological and clinical considerations. Neurol Int. 2023; 15(1):518–33.
• Zwart TC, Smits MG, Egberts TC, Rademaker CM, Van Geijlswijk IM. Long-term melatonin therapy for adolescents and young adults with chronic sleep onset insomnia and late melatonin onset: evaluation of sleep quality, chronotype, and lifestyle factors compared to age-related randomly selected population cohorts. Healthcare. 2018; 6(1):23.